In recent open-label and randomized trials, we and others have shown that GM-CSF treatment can restore innate immune responses in adult patients with severe sepsis-associated immunosuppression and in children with multiple organ dysfunction syndrome [24, 26, 34]. Here, CSF2 is linked to Sepsis.